GSK PLC (GSK) is a Zacks Rank #5 (Strong Sell) after the company beat the Zacks Consensus Estimate when the last reported. The company is in the healthcare space and there has been a lot of press ...

Chief executive Emma Walmsley said ministers must work with the sector to boost investment amid growing concerns about doing ...

GSK plc (NYSE:GSK – Get Free Report) gapped up prior to trading on Wednesday following a better than expected earnings announcement. The stock had previously closed at $34.84, but opened at $37.06.

Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

Banco Santander (BME: SAN) shares spiked over 6% on Wednesday after the lender unveiled plans for €10 billion (£8.3 billion) ...

Ms. Fogarty has served at Tonix since 2016, most recently as Executive Vice President, Product DevelopmentTonix is Preparing for Potential Launch ...

Shares of GSK plc (NYSE:GSK – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the stock, Marketbeat reports. Six ...